{"url_path":"/sec/halo/8-k/2026-07-02/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1159036/0001159036-26-000088-index.html","accession_number":"0001159036-26-000088","cik":"0001159036","ticker":"HALO","issuer_name":"HALOZYME THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1159036/0001159036-26-000088-index.html","primary_entity_key":"0001159036","primary_entity_name":"HALOZYME THERAPEUTICS, INC."},"word_count":303,"has_tables":true,"body_markdown":"halo-20260630\nFALSE000115903600011590362026-06-302026-06-30\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n____________________________________________\n\nFORM 8-K\n\n_____________________________________________\n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934\n\nDate of Report (Date of Earliest Event Reported): June 30, 2026\n\nHALOZYME THERAPEUTICS, INC.\n\n(Exact name of registrant as specified in its charter)\n\n________________________\n\nCommission File Number 001-32335\n\nDelaware 88-0488686\n\n(State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.)\n\n12390 El Camino Real 92130\n\nSan Diego(Zip Code)\n\nCalifornia\n\n(Address of principal executive offices) \n\n(858) 794-8889\n\n(Registrant’s telephone number, including area code)\n\nNot Applicable\n\n(Former name or former address, if changed since last report)\n\n________________________\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading Symbol(s)Name of each exchange on which registered\n\nCommon Stock, $0.001 par valueHALOThe Nasdaq Stock Market LLC\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).         \n\nEmerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}